FDA Approval of Stereotaxis (STXS) MAGiC Catheter Sets Stock Up for Blastoff

The approval of Stereotaxis' magnetic interventional ablation catheter is a total game-changer for the company and surely sets them up for a meteoric rise. This allows them to fully launch their US distribution.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter | Stereotaxis Inc.

Today (1/6/2025) the stock jumped 17% intraday but more upside potential beckons.

There are two major factors:

1) Johnson & Johnson just recently cancelled the manufacturing of their magnetic catheters leaving STXS as the only maker

2) There will most likely be no additional rounds of funding as STXS has taken multiple steps before this announcement to prepare for manufacturing and distribution

This follows news in 2024 of their acquisition of AccessPoint Technologies (APT):

Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies

Stereotaxis’ MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform cardiac ablation procedures that treat heart arrhythmia. The catheter is designed to expand access to minimally-invasive cardiac ablation therapy in complex underserved patient populations. The catheter is navigated by highly-precise computer-controlled magnetic fields, offering levels of catheter maneuverability, precision and stability often not possible with traditional catheters.

Interestingly enough, a search using YCharts shows that there is only one mutual fund, ETF, or pooled investment vehicle in their broad database that holds this security. Surely...that will not be the case for long!